Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Retained Earnings (2022 - 2025)

Historic Retained Earnings for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to -$447.8 million.

  • Addex Therapeutics' Retained Earnings fell 1018.1% to -$447.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$447.8 million, marking a year-over-year decrease of 1018.1%. This contributed to the annual value of -$401.7 million for FY2024, which is 9.03% down from last year.
  • As of Q3 2025, Addex Therapeutics' Retained Earnings stood at -$447.8 million, which was down 1018.1% from -$430.8 million recorded in Q2 2025.
  • In the past 5 years, Addex Therapeutics' Retained Earnings ranged from a high of -$355.2 million in Q2 2022 and a low of -$447.8 million during Q3 2025
  • For the 4-year period, Addex Therapeutics' Retained Earnings averaged around -$394.2 million, with its median value being -$394.8 million (2023).
  • In the last 5 years, Addex Therapeutics' Retained Earnings plummeted by 1292.33% in 2023 and then skyrocketed by 523.36% in 2025.
  • Addex Therapeutics' Retained Earnings (Quarter) stood at -$363.2 million in 2022, then fell by 11.88% to -$406.3 million in 2023, then increased by 0.73% to -$403.4 million in 2024, then decreased by 11.03% to -$447.8 million in 2025.
  • Its Retained Earnings was -$447.8 million in Q3 2025, compared to -$430.8 million in Q2 2025 and -$394.7 million in Q1 2025.